← Back to Browse
Ask AleraHome
ULTRASOUND
HeadDemonstration data

Transcranial Doppler Ultrasound: Sickle Cell Stroke Risk

Transcranial Doppler (TCD) ultrasound non-invasively measures cerebral arterial blood-flow velocity and is the validated tool for primary stroke prevention in children with sickle cell anaemia. Elevated velocities in the distal internal carotid and middle cerebral arteries identify children at high risk of overt stroke who benefit from chronic transfusion, as established by the STOP trial. Annual screening from age 2 to 16 years is a cornerstone of paediatric sickle cell care and is especially important in high-burden African populations.

Indications

  • Annual stroke-risk screening in children with HbSS or HbS-beta-zero thalassaemia aged 2-16 years
  • Confirmation and follow-up of previously conditional or abnormal velocities
  • Monitoring response to chronic transfusion or hydroxyurea therapy
  • Risk stratification before decisions about transfusion or transcranial-Doppler-guided management
  • Baseline assessment in a newly diagnosed child entering a stroke-prevention programme
  • Re-evaluation after clinical events or change in therapy

Contraindications & Cautions

  • No contraindications; TCD is non-invasive, non-ionising and repeatable
  • Inadequate temporal acoustic window (more common with age) may prevent interpretable insonation
  • Acute illness, fever, pain crisis, recent transfusion or sedation can transiently alter velocities - defer routine screening until the child is at steady state
  • Operator training and standardised technique are essential for validity

Patient Preparation

  • Screen at steady state, not during acute crisis, infection or shortly after transfusion
  • No fasting or sedation required; a calm, cooperative, resting child gives the best study
  • Explain the painless procedure to child and caregiver and obtain consent/assent
  • Record recent transfusion history, haemoglobin and current therapy
  • Position the child comfortably, seated or supine, with access to both temporal windows

Technique & Parameters

  • Use non-imaging (STOP-protocol) or imaging TCD; the STOP trial thresholds are based on the non-imaging technique
  • Insonate through the transtemporal window with a 2 MHz pulsed-wave probe
  • Measure time-averaged mean of the maximum velocity (TAMMV) in the distal ICA and proximal/middle MCA bilaterally
  • Interrogate anterior and posterior cerebral arteries and basilar/terminal ICA as feasible
  • Record depth, angle and window for reproducibility; use the highest reliable TAMMV to classify
  • Note that imaging (TCDI) values run approximately 10-15% lower than STOP non-imaging thresholds - apply the correct reference set

Systematic Review

  • Confirm adequate temporal windows bilaterally before interpreting
  • Measure TAMMV in both MCAs and distal ICAs
  • Document ACA, PCA and basilar velocities where obtainable
  • Compare left versus right for significant asymmetry
  • Assess waveform shape for turbulence or low-velocity signals suggesting stenosis or occlusion
  • Check for absent or very low velocity (possible high-grade stenosis/occlusion) which is also high risk
  • Cross-check values against steady-state status and recent transfusion

Key Findings & Significance

  • Abnormal (high risk): TAMMV >=200 cm/s in the ICA or MCA - indication for chronic transfusion
  • Conditional: TAMMV 170-199 cm/s - repeat within a shorter interval
  • Normal: TAMMV <170 cm/s - continue annual screening
  • Very low velocity (<70 cm/s) in a major vessel may indicate severe stenosis/occlusion and warrants MRA
  • Marked interhemispheric asymmetry raising concern for focal vasculopathy
  • STOP trial showed transfusion reduces first stroke risk by roughly 90% in the abnormal group

Differential Considerations

  • Elevated velocity: sickle vasculopathy/stenosis, anaemia-driven hyperdynamic flow, fever/crisis, technical angle error
  • Low velocity in a major artery: high-grade stenosis, occlusion, or poor insonation angle
  • Asymmetric velocities: focal stenosis, moyamoya collateralisation, congenital variant
  • Transiently high values post-anaemia correction: recent transfusion effect
  • Normal TCD with symptoms: silent infarction or small-vessel disease not detected by TCD - proceed to MRI
  • Absent signal: inadequate window versus true occlusion

Pearls & Pitfalls

  • Use the correct reference thresholds for the technique (non-imaging STOP versus imaging TCDI)
  • Screen only at steady state - acute anaemia and fever falsely elevate velocities
  • A recent transfusion lowers velocities and can mask true risk
  • Both abnormally high and abnormally low velocities carry stroke risk
  • TCD assesses stroke risk, not established infarcts - normal TCD does not exclude silent infarction
  • Confirm abnormal results before committing to lifelong transfusion; ensure consistent operator technique

Structured Report

  • State technique (imaging versus non-imaging) and adequacy of temporal windows
  • Report TAMMV for both MCAs and distal ICAs with the highest value driving classification
  • Categorise as normal, conditional or abnormal per STOP thresholds
  • Note asymmetry, low-velocity vessels or turbulent waveforms
  • Record steady-state status and recent transfusion history
  • Impression: give risk category, recommended re-screen interval or referral for transfusion, and MRI/MRA if vasculopathy suspected

References

  • Adams RJ et al., STOP Trial: Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal TCD (NEJM 1998)
  • American Society of Hematology Guidelines: Cerebrovascular Disease in Sickle Cell Disease
  • NHLBI Evidence-Based Management of Sickle Cell Disease
  • STOP protocol TCD examination standards

Educational clinical decision support only. Protocols vary by institution and equipment; always confirm with a qualified radiologist and local guidelines before clinical use.